Although J & J has in the past gone against suits that attribute cancer to its iconic baby powder, investors have not responded to losses in the courtroom. Given the scale of the price and the fact that it emerged from the first test of asbestos ovarian cancer, investors are likely to focus more on talk cases after the big award for the plaintiffs Credit Suisse analyst Vamil Divan, who rates the company's stock "outperform". Divan said he was confident J & J could "absorb even relatively large payments" to solve the cases.



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.